

Carlos Spuch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6779339/publications.pdf>

Version: 2024-02-01

67
papers

2,412
citations

236925

25
h-index

206112

48
g-index

76
all docs

76
docs citations

76
times ranked

4054
citing authors

#	ARTICLE	IF	CITATIONS
1	Prolonged oral cannabinoid administration prevents neuroinflammation, lowers $A\beta$ -amyloid levels and improves cognitive performance in Tg APP 2576 mice. <i>Journal of Neuroinflammation</i> , 2012, 9, 8.	7.2	196
2	Choroid Plexus Megalin Is Involved in Neuroprotection by Serum Insulin-Like Growth Factor I. <i>Journal of Neuroscience</i> , 2005, 25, 10884-10893.	3.6	190
3	Megalin mediates the transport of leptin across the blood-CSF barrier. <i>Neurobiology of Aging</i> , 2008, 29, 902-912.	3.1	170
4	Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: New cues into the human disease?. <i>Neurobiology of Aging</i> , 2006, 27, 1618-1631.	3.1	129
5	Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's) Tj ETQq1 1 0.784314 rgBT/Overl	2.5	123
6	The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease. <i>Biomaterials</i> , 2010, 31, 5608-5618.	11.4	114
7	Leptin Induces Proliferation of Neuronal Progenitors and Neuroprotection in a Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 17-25.	2.6	97
8	LRP-1 and LRP-2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer's disease. <i>Frontiers in Physiology</i> , 2012, 3, 269.	2.8	86
9	New Insights in the Amyloid-Beta Interaction with Mitochondria. <i>Journal of Aging Research</i> , 2012, 2012, 1-9.	0.9	86
10	Cytokines dysregulation in schizophrenia: A systematic review of psychoneuroimmune relationship. <i>Schizophrenia Research</i> , 2018, 197, 19-33.	2.0	77
11	Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles. <i>Recent Patents on Drug Delivery and Formulation</i> , 2012, 6, 2-18.	2.1	71
12	Hyperphagia and Central Mechanisms for Leptin Resistance during Pregnancy. <i>Endocrinology</i> , 2011, 152, 1355-1365.	2.8	69
13	Important role of microglia in HIV-1 associated neurocognitive disorders and the molecular pathways implicated in its pathogenesis. <i>Annals of Medicine</i> , 2021, 53, 43-69.	3.8	67
14	Cytoplasmic gelsolin increases mitochondrial activity and reduces $A\beta$ burden in a mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2009, 36, 42-50.	4.4	64
15	$A\beta$ accumulation in choroid plexus is associated with mitochondrial-induced apoptosis. <i>Neurobiology of Aging</i> , 2010, 31, 1569-1581.	3.1	63
16	A New Tacrine-Melatonin Hybrid Reduces Amyloid Burden and Behavioral Deficits in a Mouse Model of Alzheimer's Disease. <i>Neurotoxicity Research</i> , 2010, 17, 421-431.	2.7	59
17	Megalin interacts with APP and the intracellular adapter protein FE65 in neurons. <i>Molecular and Cellular Neurosciences</i> , 2010, 45, 306-315.	2.2	57
18	Ligand-independent signaling by disulfide-crosslinked dimers of the p75 neurotrophin receptor. <i>Journal of Cell Science</i> , 2009, 122, 3351-3357.	2.0	54

#	ARTICLE	IF	CITATIONS
19	Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease. <i>Molecular Brain</i> , 2014, 7, 7.	2.6	44
20	Schizophrenia: A review of potential biomarkers. <i>Journal of Psychiatric Research</i> , 2017, 93, 37-49.	3.1	44
21	Treatment of Lysosomal Storage Diseases: Recent Patents and Future Strategies. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2014, 8, 9-25.	0.6	43
22	Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on A β accumulation and cell death: Involvement in hippocampal neuronal loss in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2012, 46, 682-691.	4.4	42
23	The neurobiological hypothesis of neurotrophins in the pathophysiology of schizophrenia: A meta-analysis. <i>Journal of Psychiatric Research</i> , 2018, 106, 43-53.	3.1	40
24	The role of the gut microbiota in schizophrenia: Current and future perspectives. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 571-585.	2.6	39
25	Brainwaves Oscillations as a Potential Biomarker for Major Depression Disorder Risk. <i>Clinical EEG and Neuroscience</i> , 2020, 51, 3-9.	1.7	33
26	Present and Future of Adeno Associated Virus Based Gene Therapy Approaches. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2012, 6, 47-66.	0.6	32
27	A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine. <i>Frontiers in Psychiatry</i> , 2020, 11, 554899.	2.6	26
28	Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report. <i>Frontiers in Pharmacology</i> , 2020, 11, 557629.	3.5	23
29	Cognitive Frailty: An Update. <i>Frontiers in Psychology</i> , 2021, 12, 813398.	2.1	21
30	Plasma β -III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia. <i>Scientific Reports</i> , 2020, 10, 14271.	3.3	20
31	Gelsolin Restores A β -Induced Alterations in Choroid Plexus Epithelium. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-7.	3.0	19
32	Epistasis, physical capacity-related genes and exceptional longevity: FNDC5 gene interactions with candidate genes FOXO3 and APOE. <i>BMC Genomics</i> , 2017, 18, 803.	2.8	19
33	Proteomics in Schizophrenia: A Gateway to Discover Potential Biomarkers of Psychoneuroimmune Pathways. <i>Frontiers in Psychiatry</i> , 2019, 10, 885.	2.6	18
34	Annexin A5 prevents amyloid- β -induced toxicity in choroid plexus: implication for Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 9391.	3.3	18
35	Neurogenic effects of β -amyloid in the choroid plexus epithelial cells in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 2787-2797.	5.4	17
36	Soluble Megalin is Reduced in Cerebrospinal Fluid Samples of Alzheimer's Disease Patients. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 134.	3.7	16

#	ARTICLE	IF	CITATIONS
37	The p75 neurotrophin receptor localization in blood-CSF barrier: expression in choroid plexus epithelium. <i>BMC Neuroscience</i> , 2011, 12, 39.	1.9	15
38	tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRP. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2013, 7, 65-76.	0.6	15
39	Fibroblast Growth Factor-2 and Epidermal Growth Factor Modulate Prolactin Responses to TRH and Dopamine in Primary Cultures. <i>Endocrine</i> , 2006, 29, 317-324.	2.2	12
40	Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2). <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2010, 4, 190-205.	0.6	11
41	Changes in the Brain Extracellular Matrix Composition in schizophrenia: A Pathophysiological Dysregulation and a Potential Therapeutic Target. <i>Cellular and Molecular Neurobiology</i> , 2022, 42, 1921-1932.	3.3	9
42	GH responses to GHRH and GHRP-6 in Streptozotocin (STZ)-diabetic rats. <i>Life Sciences</i> , 2003, 73, 3375-3385.	4.3	8
43	Prolactin-releasing peptide (PrRP) increases prolactin responses to TRH in vitro and in vivo. <i>Endocrine</i> , 2007, 31, 119-124.	2.3	7
44	tPA in the central nervous system: relations between tPA and cell surface LRPs. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2013, 7, 65-76.	0.6	6
45	The Therapeutic Potential of Microencapsulate Implants: Patents and Clinical Trials. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2010, 4, 59-68.	0.6	5
46	Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2012, 6, 99-107.	0.6	5
47	Ghrelin improves growth hormone responses to growth hormone-releasing hormone in a streptozotocin-diabetic model of delayed onset. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 298-305.	3.3	4
48	Expression and Functions of LRP-2 in Central Nervous System: Progress in Understanding its Regulation and the Potential Use for Treatment of Neurodegenerative Diseases. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2010, 10, 249-254.	0.5	4
49	Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients. <i>Frontiers in Pharmacology</i> , 2022, 13, 850583.	3.5	4
50	Heparin Increases Prolactin and Modifies the Effects of FGF-2 Upon Prolactin Accumulation in Pituitary Primary Cultures. <i>Endocrine</i> , 2004, 24, 131-136.	2.2	3
51	The Role of the Second Extracellular Loop of Norepinephrine Transporter, Neurotrophin-3 and Tropomyosin Receptor Kinase C in T Cells: A Peripheral Biomarker in the Etiology of Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8499.	4.1	3
52	Proteomic and metabolic profiling of chronic patients with schizophrenia induced by a physical activity program: Pilot study. <i>Revista De Psiquiatria e Saude Mental (English Edition)</i> , 2021, 14, 125-138.	0.3	2
53	Cell Microencapsulation Implants into the Central Nervous System. <i>Recent Patents on Nanomedicine</i> , 2011, 1, 60-67.	0.5	2
54	The Therapeutic Potential of Cell Encapsulation Technology for Drug Delivery in Neurological Disorders. , 0, ,		2

#	ARTICLE	IF	CITATIONS
55	New Insights in Prolactin Releasing Peptide (Prpp) in the Brain. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2011, 11, 228-233.	0.5	1
56	Mania as Debut of Cushing's Syndrome. Case Reports in Psychiatry, 2020, 2020, 1-3.	0.5	1
57	Hyperphagia and Central Mechanisms for Leptin Resistance during Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 869-869.	3.6	1
58	tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRP5. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012, 7, 65-76.	0.6	1
59	Effectiveness of the 'Trisquel' board game intervention program for patients with schizophrenia spectrum disorders. Actas Espanolas De Psiquiatria, 2020, 48, 209-219.	0.1	1
60	Voices 2: Improving Prosodic Recognition in Schizophrenia With an Online Rehabilitation Program. Frontiers in Psychology, 2021, 12, 739252.	2.1	1
61	Induction of angiogenesis by implantation of encapsulated cells expressing vegf: A new therapy approach on Alzheimer's disease?. Journal of the Neurological Sciences, 2009, 283, 260.	0.6	0
62	Protection by gelsolin on amyloid- β -induced toxicity in the blood-CSF-brain barrier: Apoptotic pathways. Journal of the Neurological Sciences, 2009, 283, 299.	0.6	0
63	P1533: DO BIOMARKERS DIFFERENTIATE COGNITIVE PROFILES IN MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE?. Alzheimer's and Dementia, 2018, 14, P536.	0.8	0
64	Perfil proteómico y metabólico de pacientes crónicos con esquizofrenia tras un programa de actividad física: estudio piloto. Revista De Psiquiatría Y Salud Mental, 2021, 14, 125-138.	1.8	0
65	Cell Microencapsulation Implants into the Central Nervous System. Recent Patents on Nanomedicine, 2011, 1, 60-67.	0.5	0
66	Perfil neuropsicológico y sintomatología psicopatológica de pacientes con trastornos relacionados con sustancias a tratamiento en una unidad de día. Health and Addictions / Salud Y Drogas, 2019, 19, 70-79.	0.2	0
67	Efficacy of the Therapeutic Game 'Trisquel' in the Treatment of Patients With Substance-Related Disorders Randomized Clinical Study. Frontiers in Psychiatry, 2022, 13, 864511.	2.6	0